The overexpression of CD38 on malignant plasma cells makes CD38 an ideal target for immunotherapy in multiple myeloma (MM) [21, 22]; and a potential target in adult acute myeloid leukemia (AML) and T-cell acute lymphoblastic leukemia (T-ALL) [23–25]. The gene discussed is CD38; the disease is plasma cell myeloma.